Cargando…

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients

The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Blom, Thomas, Lurvink, Roosmarijn, Aleven, Leonie, Mensink, Maarten, Wolfs, Tom, Dierselhuis, Miranda, van Eijkelenburg, Natasha, Kraal, Kathelijne, van Noesel, Max, van Grotel, Martine, Tytgat, Godelieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925836/
https://www.ncbi.nlm.nih.gov/pubmed/33680926
http://dx.doi.org/10.3389/fonc.2020.601076
_version_ 1783659337407791104
author Blom, Thomas
Lurvink, Roosmarijn
Aleven, Leonie
Mensink, Maarten
Wolfs, Tom
Dierselhuis, Miranda
van Eijkelenburg, Natasha
Kraal, Kathelijne
van Noesel, Max
van Grotel, Martine
Tytgat, Godelieve
author_facet Blom, Thomas
Lurvink, Roosmarijn
Aleven, Leonie
Mensink, Maarten
Wolfs, Tom
Dierselhuis, Miranda
van Eijkelenburg, Natasha
Kraal, Kathelijne
van Noesel, Max
van Grotel, Martine
Tytgat, Godelieve
author_sort Blom, Thomas
collection PubMed
description The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of this study was to describe treatment-related toxicities during immunotherapy with dinutuximab, IL-2, GM-CSF, and isotretinoin. A retrospective, single center analysis of immunotherapy-related toxicities was performed in twenty-six consecutive high-risk neuroblastoma patients who received immunotherapy as maintenance therapy in the Princess Máxima Center (Utrecht, Netherlands). Toxicities were recorded and graded according to the CTCAE. Particular attention was drawn to pain and fever management and toxicities leading to dose modifications of dinutuximab and IL-2. Twenty-three patients (88%) completed all six courses of immunotherapy. Disease progression, isotretinoin-associated liver toxicity, and catheter-related infection in combination with peripheral neuropathy were reasons for immunotherapy discontinuation. The most common grade ≥3 toxicities for courses 1–5, respectively, were pain, catheter-related infections, and fever. In total, 310 grade ≥3 toxicities were recorded in 124 courses. Thirty-three grade 4 toxicities in 19/26 patients and no grade 5 toxicities (death) were seen. Fifty-nine percent of grade ≥3 toxicities were recorded in the two courses with IL-2. Catheter-related bloodstream infections were identified in 81% of patients. Four of these episodes led to intensive care admission followed by full recovery (grade 4).
format Online
Article
Text
id pubmed-7925836
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79258362021-03-04 Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients Blom, Thomas Lurvink, Roosmarijn Aleven, Leonie Mensink, Maarten Wolfs, Tom Dierselhuis, Miranda van Eijkelenburg, Natasha Kraal, Kathelijne van Noesel, Max van Grotel, Martine Tytgat, Godelieve Front Oncol Oncology The introduction of immunotherapy using an anti-GD2 antibody (dinutuximab, ch14.18) has significantly improved survival rates for high-risk neuroblastoma patients. However, this improvement in survival is accompanied by a substantial immunotherapy-related toxicity burden. The primary objective of this study was to describe treatment-related toxicities during immunotherapy with dinutuximab, IL-2, GM-CSF, and isotretinoin. A retrospective, single center analysis of immunotherapy-related toxicities was performed in twenty-six consecutive high-risk neuroblastoma patients who received immunotherapy as maintenance therapy in the Princess Máxima Center (Utrecht, Netherlands). Toxicities were recorded and graded according to the CTCAE. Particular attention was drawn to pain and fever management and toxicities leading to dose modifications of dinutuximab and IL-2. Twenty-three patients (88%) completed all six courses of immunotherapy. Disease progression, isotretinoin-associated liver toxicity, and catheter-related infection in combination with peripheral neuropathy were reasons for immunotherapy discontinuation. The most common grade ≥3 toxicities for courses 1–5, respectively, were pain, catheter-related infections, and fever. In total, 310 grade ≥3 toxicities were recorded in 124 courses. Thirty-three grade 4 toxicities in 19/26 patients and no grade 5 toxicities (death) were seen. Fifty-nine percent of grade ≥3 toxicities were recorded in the two courses with IL-2. Catheter-related bloodstream infections were identified in 81% of patients. Four of these episodes led to intensive care admission followed by full recovery (grade 4). Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7925836/ /pubmed/33680926 http://dx.doi.org/10.3389/fonc.2020.601076 Text en Copyright © 2021 Blom, Lurvink, Aleven, Mensink, Wolfs, Dierselhuis, van Eijkelenburg, Kraal, van Noesel, van Grotel and Tytgat http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Blom, Thomas
Lurvink, Roosmarijn
Aleven, Leonie
Mensink, Maarten
Wolfs, Tom
Dierselhuis, Miranda
van Eijkelenburg, Natasha
Kraal, Kathelijne
van Noesel, Max
van Grotel, Martine
Tytgat, Godelieve
Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
title Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
title_full Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
title_fullStr Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
title_full_unstemmed Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
title_short Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
title_sort treatment-related toxicities during anti-gd2 immunotherapy in high-risk neuroblastoma patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925836/
https://www.ncbi.nlm.nih.gov/pubmed/33680926
http://dx.doi.org/10.3389/fonc.2020.601076
work_keys_str_mv AT blomthomas treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT lurvinkroosmarijn treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT alevenleonie treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT mensinkmaarten treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT wolfstom treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT dierselhuismiranda treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT vaneijkelenburgnatasha treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT kraalkathelijne treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT vannoeselmax treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT vangrotelmartine treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients
AT tytgatgodelieve treatmentrelatedtoxicitiesduringantigd2immunotherapyinhighriskneuroblastomapatients